MBX — Microbix Biosystems Income Statement
0.000.00%
- CA$41.04m
- CA$34.88m
- CA$16.51m
- 73
- 56
- 54
- 64
Annual income statement for Microbix Biosystems, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 13.4 | 10.5 | 18.6 | 19.1 | 16.5 |
Cost of Revenue | |||||
Gross Profit | 6.55 | 4.66 | 11 | 11.1 | 7.48 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 13.4 | 15.2 | 15.4 | 17.2 | 16.6 |
Operating Profit | 0.044 | -4.66 | 3.23 | 1.87 | -0.039 |
Net Income Before Taxes | 0.044 | -4.66 | 3.23 | 1.87 | -0.039 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.032 | -6.23 | 3.23 | 1.79 | -0.039 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.032 | -6.23 | 3.23 | 1.79 | -0.039 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.032 | -6.23 | 3.23 | 1.79 | -0.039 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0 | -0.04 | 0.023 | 0.013 | -0.023 |